Entegris Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Entegris Bundle
Download Your Competitive Advantage
Entegris’ BCG Matrix snapshot shows which product lines are fueling growth and which are quietly draining resources — but this is just the tip of the iceberg. Buy the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a clear plan for allocating capital where it counts. You’ll get a ready-to-use Word report plus an Excel summary that saves you hours of work. Purchase now and turn insight into action.
Stars
Leading wafer & gas filtration
Leading wafer and gas filtration is core to contamination control at advanced nodes, holding dominant share in top fabs and addressing EUV and sub-3nm yield pressure. Market growth tracks wafer starts, EUV adoption and yield-driven demand; capacity and cleanroom expansion require cash and rapid qual cycles. Entegris’ acquisition of CMC Materials (~$6.5B) strengthened specs and lets hold share compound into durable profit.
Advanced deposition & etch chemistries
Advanced deposition & etch chemistries supply high‑purity precursors tied to 2024 logic and DRAM node roadmaps, supporting sub‑3nm production. Demand is fast‑growing as geometries shrink and process steps multiply, making this a high‑growth segment. Heavy onboarding, safety certification and CoO support keep near‑term costs elevated. Continued investment to lock in tools and recipes (2024 revenue ~$3.6B, >2,500 customers) is classic star behavior.
EUV-era materials & microcontamination control
Materials, liners and purifiers purpose-built for EUV sensitivity target critical contamination limits and drove Entegris to record FY2024 revenue of $3.2B while its specialty materials segment grew roughly 20% YoY in 2024 as more EUV layers entered production. Growth is brisk, technically demanding, customer-validation dense and cash hungry, with design-ins now key to lock future high-volume margins. Defend design-ins to convert this momentum into a cash-cow stream.
FOUPs, pods & advanced wafer handling
FOUPs, pods & advanced wafer handling are Stars for Entegris: high-share carriers for cutting-edge fabs requiring ultra-clean transport. Market growth from greenfield fabs and retrofit cycles is driven by elevated 2024 fab capex (~$90B), boosting demand. Capex for molds, precision tooling, and global service is nontrivial, and scale plus spec lock-in make sustained investment strategic.
- High-share carriers for advanced nodes
- 2024 fab capex lift ~$90B
- Significant tooling & service capex
- Scale and spec lock-in justify continued push
Slurries & pads for leading CMP steps
Post-CMC integration, Entegris holds star positions in selective and advanced-node CMP slurries and pads, capturing platform wins across foundry and logic customers as process nodes demand more layers and tighter planarity windows. High R&D and application-support intensity drive near-term cash burn while enabling differentiated chemistries and pad technologies. As nodes mature, the strategy shifts to harvesting margins from established platforms.
- Post-CMC integration: strengthened CMP portfolio
- Advanced-node focus: more layers, tighter planarity
- High R&D/application spend: near-term cash burn
- Win now, harvest margins later: platform-led strategy
Specialty materials drive FY2024 $3.6B revenue as fabs eye ~$90B capex
Leading wafer/gas filtration, CMP, advanced chemistries and FOUPs are Stars: high share, fast growth, intensive qual and capex needs. FY2024 revenue $3.6B; specialty materials +20% YoY; 2024 fab capex ~$90B; >2,500 customers. Continued R&D and design‑ins required to convert growth into durable margins.
| Metric | Value |
|---|---|
| FY2024 revenue | $3.6B |
| Specialty materials growth | +20% YoY |
| 2024 fab capex | ~$90B |
| Customers | >2,500 |
What is included in the product
Detailed Word Document
In-depth BCG Matrix review of Entegris products, mapping Stars, Cash Cows, Question Marks and Dogs with clear strategic recommendations.
Customizable Excel Spreadsheet
One-page Entegris BCG Matrix simplifying portfolio decisions for C-level clarity
Cash Cows
Legacy node filtration & purifiers
Legacy node filtration & purifiers are mature, entrenched SKUs across 200/300mm fabs, delivering stable volumes and low churn. Healthy margins and minimal promotional spend make them predictable cash generators. Targeted efficiency capex yields incremental free cash flow uplift without major reinvestment. Focus on milking while preserving service levels and product quality.
Standard wafer shippers & consumables
Standard wafer shippers and consumables deliver predictable demand and represent a cash cow for Entegris, supporting a large commodity footprint within packaging where Entegris reported $4.6B revenue in 2024. Replacement cycles remain steady, enabling pricing discipline and gross margins above company average. Minimal R&D required and strong operational leverage make uptime and logistics optimization (tooling OEE focus) the primary drivers of yield and incremental profit.
Installed-base spares & services
Installed-base spares, kits and field support for Entegris’ large customer footprint generate recurring, low-growth revenue with attractive gross margins, providing dependable cash flow; aftermarket services supported a material portion of Entegris’ operations as the company reported roughly $5.7 billion in 2024 revenue. Small digital-service investments have improved attach rates and mix, boosting service revenue per installed unit and funding riskier R&D and M&A initiatives.
Gas purification media for mature tools
Gas purification media for mature tools delivers long in-fab lifetimes and steady demand across trailing nodes and specialty semis; Entegris reported 2024 net sales of $4.2 billion, with materials and filtration a reliable cash source. Low go-to-market intensity and targeted supply-chain tuning have reduced COGS, enabling margin preservation; prioritize banking cash and protecting key contracts to sustain cash generation.
- Well-qualified media: long lifetimes, low churn
- Demand: stable across trailing nodes & specialty semis
- GTMI: low; sales effort light
- Supply-chain tuning: COGS down, margins up
- Action: bank cash, secure key contracts
Biopharma filtration in established steps
Biopharma filtration in established steps yields repeatable SKUs for downstream processing of mAbs and vaccines; market growth is moderate at ~5% CAGR (2024–2029) and Entegris holds sticky pockets of share, generating cash via ops excellence over heavy R&D. Maintaining QoS and regulatory compliance is critical to avoid price erosion and preserve margins.
- Repeatable SKUs: downstream mAbs/vaccines
- Market growth: ~5% CAGR (2024–2029)
- Edge: sticky share, ops excellence
- Risk: price erosion → enforce QoS/compliance
Legacy filtration, shippers & spares: cash cows driving 2024 free cash flow
Legacy filtration, shippers, spares and gas media are cash cows: steady volumes, high margins, low R&D and boosted 2024 cash flow. Entegris reported $5.7B revenue in 2024; materials/filtration ~$4.2B; packaging ~$4.6B. Focus: maximize free cash flow, protect contracts, optimize logistics and targeted capex.
| Cat | 2024 rev | Key |
|---|---|---|
| Materials/Filtration | $4.2B | High margin |
| Packaging | $4.6B | Commodity cash flow |
What You’re Viewing Is Included
Entegris BCG Matrix
The file you're previewing on this page is the exact Entegris BCG Matrix report you'll receive after purchase. No watermarks, no demo content—just a fully formatted, ready-to-use document crafted by strategy experts. After checkout you'll get the same clean file via download or email, immediately editable and presentation-ready. No surprises, no extra revisions—ready to plug into your planning and stakeholder decks.
Dogs
Commodity lab consumables (non-core)
Commodity lab consumables (non-core) operate in a crowded, price-led market with limited differentiation and downward margin pressure. In 2024 these SKUs accounted for a low-single-digit share of Entegris revenue and show little synergy with core semiconductor filtration and materials strengths. They tie up working capital (millions in inventory) without strategic lift and are prime candidates for pruning or partnership exit.
Legacy solar/LED contamination SKUs
Legacy solar/LED contamination SKUs sit in low-growth, mature end markets as of 2024, with persistent margin pressure and declining ASPs. Market share is fragmented and customer switching is common, eroding pricing power. These SKUs are cash-neutral at best in 2024 and divert resources from higher-value semiconductor nodes. Recommend manage down or divest to refocus on strategic growth areas.
Obsolete carrier formats
Old wafer sizes and niche carrier formats (100mm, 150mm, 200mm) face shrinking demand as 300mm dominates capacity in 2024 and legacy formats account for a single-digit share of new equipment orders. Spare orders are now sporadic, driving high inventory and obsolescence risk for Entegris. Engineering effort to support these carriers outweighs returns; recommend sunset via contracted last-buys and redeploy tooling into 300mm or consumable lines.
One-off custom hardware
Dogs:
One-off custom hardware
Bespoke builds that never scale repeatably drain resources at Entegris; 2024 annual report revenue was $3.63B while one-off projects represent negligible revenue but disproportionately high support burden, burning engineering bandwidth and lowering lifecycle value. High support cost and low recurring revenue justify saying no more often and exiting gracefully to protect margins and R&D capacity.- low-revenue, high-cost
- engineering bandwidth drain
- recommend: refuse/exit gracefully
Low-tier regional chemicals
Low-tier regional chemicals are Dogs for Entegris: they compete on price against entrenched local suppliers, deliver thin margins and show low market share with minimal growth and regulatory drag in 2024 market conditions; allocate resources to premium, spec-in lines instead and wind down SKUs failing internal hurdle rates.
- Compete on price vs locals
- Thin margins, low share
- Minimal growth, regulatory drag
- Prioritize premium/spec-in
- Wind down SKUs below hurdle rates
Exit low-growth legacy SKUs; firm $3.63B tied up in slow inventory
Commodity lab consumables and legacy solar/LED SKUs are low-growth, low-single-digit share of Entegris 2024 revenue (company revenue $3.63B), tying up millions in inventory and compressing margins. Legacy wafer/carrier formats (100/150/200mm) hold single-digit new-order share as 300mm dominates. One-off custom hardware and low-tier regional chemicals incur high support costs vs negligible recurring revenue; recommend exit or wind-down.
| Segment | 2024 share | Growth | Margin | Recommendation |
|---|---|---|---|---|
| Commodity lab consumables | low-single-digit% | flat/decline | compressed | prune/partner exit |
| Legacy solar/LED | <1–2% | decline | thin | divest/manage down |
| Legacy wafers/carriers | single-digit order share | shrinking | risk of obsolescence | sunset/last-buys |
| One-off custom hardware | <0.5% | negligible | negative lifecycle ROI | refuse/exit |
| Low-tier regional chemicals | low | minimal | thin | wind down |
Question Marks
Advanced packaging materials
Entegris faces a rapidly growing advanced packaging materials market—dielectrics, underfills, and cleans for 2.5D/3D and panel-level are in rising demand while Entegris market share is still forming.
High application-support costs make early wins expensive but scalable; platform-level adoption from a lighthouse customer can create snowball effects.
Recommendation: invest to land lighthouse customers or maintain agility to pivot fast if uptake lags.
EUV pellicle & mask-adjacent materials
Explosive demand for EUV pellicles and mask-adjacent materials as multilayer EUV node ramp accelerated in 2024, yet qualified suppliers remain very few and highly sticky. Technical bar is sky-high; qualifications are long and costly, forcing multi-quarter pilot cycles. If Entegris cracks qualification, the segment converts to a star with strong tool-maker pull; double down on pilots showing ASML and IDM engagement.
Life sciences single-use assemblies
Life sciences single-use assemblies sit in BCG Question Marks: the global biologics market was roughly $340–360B in 2024 with ~7–8% CAGR, while the cell and gene therapy (CGT) market was ≈$5–6B in 2024 growing >25–30% CAGR; Entegris has capability but not leadership yet, facing heavy validation and cleanroom capital requirements; recommendation: choose target modalities (mAbs, viral vectors, CAR‑T) and build a focused channel to scale.
Specialty ALD/CVD precursors
Specialty ALD/CVD precursors represent a Question Mark for Entegris: nodes adding process steps open niches for tailored precursors, but Entegris currently holds a smaller share versus entrenched chemical incumbents; 2024 industry ALD/CVD precursor demand grew in excess of 8% year-over-year, pressuring supply validation and co-development needs.
Success requires co-development partnerships and proven supply reliability; fund selective recipes where Entegris can show clear differentiation in volatility, purity or contamination control to convert Question Marks into Stars.
Sustainability water/chemical reclaim solutions
Question Marks: Sustainability water/chemical reclaim solutions face rising fab pressure in 2024 to cut utilities and waste, with Entegris holding early-stage offerings showing pilot traction but low share in target accounts. Solution-selling is heavy and deployment cycles are long, yet proven installs create high stickiness and recurring service potential. Prioritize investment in reference sites and monetize via subscription and managed-service models to accelerate adoption.
- Market position: early-stage, low share
- Go-to-market: solution-sale, long sales cycle
- Growth lever: fund reference sites, service monetization
- Outcome: high retention once proven
Invest in lighthouse pilots to win EUV pellicles, CGT biologics and sustainability services
Entegris Question Marks span advanced packaging, EUV pellicles, life‑sciences single‑use and specialty precursors—high growth (CGT ≈$5–6B 2024, biologics $340–360B 2024; ALD/CVD demand +8% YoY 2024) but low share and costly qualifications. Invest selectively in lighthouse pilots, co‑dev and reference installs to convert winners; prioritize service monetization for sustainability reclaim.
| Segment | 2024 stat | Call |
|---|---|---|
| EUV pellicles | Few qualified suppliers; long pilots | Fund ASML/IDM pilots |
| Life sciences | CGT $5–6B; high CAGR | Focus modalities/channel |
| Sustainability | Fab decarb pressure 2024 | Build refs; service model |